"Our own product" is a phrase doing quiet work in most brand decks. Two founders can say it with equal sincerity and mean entirely different things. One owns a name printed on a bottle whose contents belong to someone else. The other owns the contents too — the formula, its documentation, and the right to have it made anywhere. Both are legitimate businesses, and both feel identical from the outside. The trouble is that the private label vs custom formula decision is usually made on cost and speed, and only discovered later to have been a decision about ownership.
We compared the three manufacturing models — cost, speed, risk — in OEM vs ODM vs private label. This article takes the one axis that outlives all the others and follows it to the end. When you launch on a manufacturer's formula, or develop your own, what is actually yours: on the day you launch, on the day a competitor imitates you, and on the day you want to move.
What Private Label Makes Yours
A private label product is often described as "your brand on someone else's formula". The description is accurate, but it undersells both halves. Start with what the brand half actually contains.
The trademark is yours, and with it the name customers ask for. The artwork and pack design you commissioned are yours. So is everything they add up to — the position you occupy, the story you tell, the audience you have gathered, the channel relationships you have built. Above all, the sell-through record is yours: real evidence of what your customers buy, at what price, and how often they come back. Durable cosmetics businesses have been built on exactly this set of assets and nothing more. Ownership of the outside of the product is genuine ownership. It is simply ownership of the outside.
What is not yours is the inside. The formula belongs to the manufacturer, and so does everything attached to it: the quantitative composition, the processing know-how, and the testing history that proves the product survives its shelf life. That has two consequences which surface at the worst possible moments.
The first is that you cannot exclude anyone. The base offered to you is offered to others, and nothing you own gives you the right to stop a competitor from launching on it. Your defence is the brand you built around the product, not the product.
The second is that you cannot take the inside with you. If the relationship ends — pricing, capacity, a dispute, a factory decision to retire the base — the formula stays where it always lived. You leave with the outside of a product and can commission something similar elsewhere, but similar is not identical, and your most loyal customers are precisely the ones who will notice.
What Owning a Formula Actually Means
The part that surprises brands who have never bought one: a formula, as an ownable asset, is not a texture you can point to in a jar. It is a document set. The quantitative composition. The raw material specifications, with named suppliers and grades. The manufacturing process — order of addition, temperatures, mixing conditions. And the testing records that demonstrate the whole thing holds together over time. To own a formula is to hold those documents and the right to take them to another factory.
That definition matters because ownership short of it is weaker than it sounds. A brand can "own" a formula on paper and still be unable to move it, because a composition without its process and its testing history has to be partly rebuilt at the next factory — paid for again, in money and in calendar.
The price of getting there is real. Developing a formula of your own — through ODM development against your brief or a custom formulation project — means development fees, prototype rounds, and a testing programme that occupies calendar time no payment can compress. It also means volume: development economics rest on the first production runs, which is why formula ownership and minimum order pressure arrive together. How that pressure works, and which levers bring a minimum order down, we have covered separately; the short version is that owning the inside of your product is a commitment, not a purchase.
And ownership continues after launch. Your formula's performance is your responsibility, its documentation is your burden to keep current, and its testing and quality records are part of what you now maintain. Brands that want the asset without the upkeep discover that the upkeep is the asset.
Where the Agreement Draws the Line
None of what follows is legal advice, and we are not the right party to interpret a contract for you — that is what your own counsel is for. What we can tell you, from the manufacturing side of the table, is which questions decide ownership in practice. The answers belong in writing, before development starts, because every one of them is easier to settle while the formula does not yet exist.
Disclosure. Will you ever see the full quantitative formula, or only the ingredient declaration on the label? There is a wide space between the two, and a formula you have never seen is difficult to call yours in any practical sense. Ask what you will hold in your hands, and when.
Exclusivity. If the formula is developed against your brief, can the manufacturer offer it — or a close relative of it — to someone else? In your category, in your market, in your channel, and for how long? Each of those is a separate question with a separate answer, and silence on any of them is an answer too.
Portability. If you move production one day, what moves with you? The composition, the process parameters, the stability and compatibility data, the packaging tooling you may have paid for, the artwork files — each has a different natural home, and none of them travels by default. The moment to ask is before the first purchase order, not during the dispute that makes you want to leave.
Improvements. Formulas drift across a production life. Raw materials get substituted, processes get tuned, a preservative system gets updated. If the original formula is yours, is the revised one? Brands rarely ask this, and the ambiguity compounds quietly for years before it matters all at once.
The Middle Ground: An Exclusive Variant of a Shared Base
Between the catalogue and the blank page sits an arrangement worth understanding on its own terms: the manufacturer's base, carrying your variation — a fragrance, an active added or raised, a texture adjustment. It is faster and cheaper than developing from zero, and the variation itself can be exclusive to you.
Its ownership shape is a hybrid, and both halves matter. The variation may be yours; the base underneath it is not, and never becomes so. Exclusivity on the variant does not prevent another brand from commissioning its own variant of the same base, and the family resemblance between cousins can be closer than either brand would like. Portability is the sharper limit: your variation is defined relative to a base you cannot take with you, so what you own is, in effect, anchored to the factory that owns what it stands on.
None of that makes it a bad arrangement. It is often the right first step — genuine differentiation at a fraction of the commitment. It only goes wrong when a brand believes it has bought the whole stack and builds its story on a foundation it turns out to be renting.
Match the Ownership to the Stage
The honest answer to "which is right" is that ownership should follow proof, not ambition.
Before a product has sold, the assets a private label programme gives you are the ones you can actually use: a position, a channel, and — most valuable of all — evidence. Formula ownership at this stage is expensive insurance on a product the market has not yet endorsed, bought with capital the brand side of the business badly needs.
After a hero product has proven itself, the calculus inverts. Now the formula is worth owning precisely because you know what it earns: ownership brings supply security, freedom to move, control over the product's evolution — and if the business is ever valued or sold, what you own is what gets counted. The common sequence is not a compromise but a strategy: launch wide on shared formulas, learn what deserves to be owned, then own it.
The mistake runs in either direction — owning nothing long after a hero product deserved better, or owning everything before anything was proven.
Frequently Asked Questions
Can I buy the formula behind my private label product?
Sometimes, but less often than brands hope. A base offered across many brands usually cannot be sold to one of them, because the manufacturer would be selling the same asset out from under its other customers. The realistic routes are an exclusive variant of that base, or a new formula developed with what your sell-through data taught you. Ask early either way — the answer shapes your options later.
If I change manufacturers, what actually moves with me?
Whatever the agreement says moves, and very little moves by default. In a private label relationship that is typically the outside of the product: your trademark, your artwork, and any tooling the agreement assigns to you. The formula and its testing history typically stay. If you own the formula, the document set travels — though even then, transferring a product between factories is a technical project in its own right, not a courier shipment.
Who owns improvements made to my formula over time?
It depends entirely on what was agreed, which is why it belongs in the agreement rather than in assumption. Production-life changes — substituted raw materials, tuned processes, updated preservation — accumulate until the running version and the version you own may no longer be the same document. Ask how revisions are recorded, and whether they attach to your ownership or to the manufacturer's know-how, before the first one happens.
Is an exclusive variant the same as owning the formula?
No. The variation can be exclusively yours while the base it stands on remains the manufacturer's, and exclusivity on your variant does not stop other brands from commissioning their own variants of the same base. That does not make the arrangement a trap — but the brand should know which layer it owns before building a story, or a valuation, on the whole stack.